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Abstract
T-prolymphocytic leukemia (T-PLL), a rare aggressive mature T-cell disorder, remains frequently resistant
to conventional chemotherapy. Studies have suggested that allogeneic hematopoietic stem cell
transplantation (HSCT) might possibly serve to consolidate the response to initial chemotherapy. The
current report summarizes the outcome of 27 T-PLL cases identified in the registry in French Society for
stem cell transplantation (SFGM-TC). Prior to HSCT, 14 patients were in complete remission (CR), 10 in
partial response, three refractory, or in progression. Following HSCT, 21 patients achieved CR as best
response. With a median follow-up for surviving patients of 33 (range, 6–103) months, 10 patients are still
alive in continuous CR. Overall survival and progression-free survival estimates at 3 yr were 36% (95% CI:
17–54%) and 26% (95% CI: 14–45%), respectively. The relapse incidence after HSCT was 47% occurring
at a median of 11.7 (range, 2–24) months. Overall cumulative incidence of transplant-related mortality was
31% at 3 yr. These results suggest that HSCT may allow long-term survival in patients with T-PLL
following induction treatment; however, it is associated with a significant rate of toxicity.
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T-prolymphocytic leukemia (T-PLL) is a rare aggressive
mature T-cell disorder with distinctive clinical, morphologic,
immunophenotypic, and cytogenetic characteristics (1, 2).
Indolent forms of the disease with moderate and isolated
lymphocytosis have been described, but they usually pro-
gress to aggressive forms months or years later (3). Two
proto-oncogenes TCL1a (14q32.1) and MTCP1 (Xq28) are
involved in the pathogenesis of T-PLL while deletions or
mutations of ataxia telangiectasia mutation in 11q23 have
been involved in the sporadic and AT-associated T-PLL.
T-PLL remains frequently resistant to conventional therapy.
Median overall survival (OS) is approximately 7 months
with such chemotherapy. The use of the anti-CD52 monoclo-
nal antibody alemtuzumab could improve overall response
rate (4, 5). Alemtuzumab given intravenously as ﬁrst-line
treatment resulted in an overall response rate of 91% with
81% completed response (6). More recently, Hopﬁnger et al.,
(7) used Fludarabine, mitoxantrone, and cyclophosphamide
induction followed by alemtuzumab consolidation (FMC-A).
For those who received the consolidation, the overall response
rate reached 92%, with median OS of 17.1 months and med-
ian progression-free survival (PFS) of 11.9 months. In an
attempt to improve survival, isolated case reports have sug-
gested that allogeneic hematopoietic stem cell transplantation
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(HSCT) may serve to consolidate the response to initial
chemo-immunotherapy in T-PLL (8–14). The present report,
we analyze the outcome of 27 T-PLL patients who received
HSCT and were reported to the SFGM-TC registry.
Patients and methods
The current retrospective analysis includes 27 patients fulﬁll-
ing the criteria for T-PLL (1) who underwent HSCT and
had been reported to the registry of the SFGM-TC between
2000 and 2013. Patients were treated in 17 French and Bel-
gian centers. This study was approved by the scientiﬁc com-
mittee of the SFGM-TC and conducted according to the
principle of the Declaration of Helsinki. For the purpose of
this analysis, a speciﬁc case report form was designed and
centers were required to provide full diagnosis, transplant,
and outcome data.
The analysis assessed pre- and post-transplant disease
response, OS, PFS, transplant-related mortality (TRM), dis-
ease progression, and cumulative incidences of acute and
chronic graft-versus-host disease (GVHD). OS and PFS were
estimated using the Kaplan–Meyer method, while cumulative
incidence rates were used for progression, TRM, and GVHD
incidences with death or relapse treated as competing events.
Potential prognostic factors including age, conditioning regi-
men (myeloablative vs. reduced-intensity regimen), total
body irradiation (TBI) use as part of conditioning, type of
donor (sibling vs. unrelated donor), graft source (peripheral
blood stem cell vs. bone marrow or cord blood), stage of
disease at transplantation, presence of acute or chronic
GVHD were studied in univariate analyses. The log-rank test
was used for univariate comparisons (GRAPHPAD software, La
Jolla, CA, USA). Given the small number of patients, multi-
variate analysis was not performed.
Results
Patients’ characteristics are summarized in Table 1. Prior
to HSCT, 14 patients were in complete (CR), 10 in partial
response (PR), three refractory, or in progression. One
patient who received a second transplant was in PR prior
to the second transplantation. Alemtuzumab was used in
17 patients prior to transplant (14 as ﬁrst line, reused as
second-line therapy for one patient, and as third line for
three patients), ﬂudarabine was used in four patients (two
as ﬁrst line and reused with associated with cyclophospha-
mide for one patient as second line, two patients received
ﬂudarabine associated with mitoxantrone and cyclophospha-
mide as second line and third line), and pentostatin was
used in seven patients (two as ﬁrst line or 5 second line).
A CHOP-like regimen was used in 10 patients (eight as
ﬁrst line, two as second line and reused as second line for
one patient). Alemtuzumab was administered subcutane-
ously for all patients.
Table 1 Patient, disease, and transplant characteristics
Patient, N 27
Transplants, N 281
Median age at transplant (yr, range) 53 (36–65)
Male/female ratio 17/10















Not done or failed 10


















Source of stem cells
Bone marrow 4
Peripheral blood stem cells 201
Cord blood 4




1One pt received a second RIC allotransplant.
2Defined according to Bacigalupo et al. (17).
Table 2 Pretransplant status response and the best response post-
transplant
PR ? CR 7
Progression or refractory ? CR 2
CR ? CR 12
PR ? PR 41
CR ? not evaluable 1
Progression ? not evaluable 1
CR ? early relapse 1
PR, partial response; CR, complete remission.
1One pt received a second RIC allotransplant.
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Following transplantation, as best response, 21 patients
were in CR1. For two patients, response could not be deter-
mined due to early TRM. The pretransplant status and post-
transplant best response are summarized on Table 2. After
HSCT, engraftment was achieved in 96% of the patients.
With a median follow-up for surviving patients of 33 (range,
6–103) months, 10 patients are still alive all in CR. OS and
PFS estimates at 3 yr were 36% (95% CI: 17–54%) and
26% (95% CI: 14–45%), respectively (Fig. 1A). Seventeen
patients died, six from transplant-related causes (namely four
GVHD, one infection, one cardiac toxicity) eight due to
disease progression, one from neoplastic pericarditis, and
two from unknown reason.
At last follow-up, the relapse incidence was 47% (Fig. 1B).
Relapse was observed at a median of 11.7 (range, 2–24)
months after HSCT. Among the 11 patients who relapsed, the
relapse was observed beyond 1 yr for ﬁve of them. Ten
patients were retreated for post-transplantation relapse.
Details of salvage therapy are given on Table 3. Overall
cumulative incidence of TRM was 31% at 3 yr (Fig. 1C).
Donor lymphocyte infusions (DLI) were performed in six
patients (ﬁve for disease relapse and one for mixed donor chi-
merism). It was efﬁcient in only two cases: a CR was
obtained for one patient who unfortunately developed a grade
4 acute digestive GVHD and died from pulmonary carci-
noma; mixed chimerism was corrected for the other patient.
Six patients (22%) had a prolonged survival beyond
36 months. One died from unknown reason at 51 months
from transplantation but not due to relapse, and another one
died at 53 months because of relapse (the relapse was trea-
ted with alemtuzumab and DLI).
Fifteen patients developed acute GVHD (grade I in
three patients, grade II in eight patients, grade III in three
patients, and grade IV in one patient). The cumulative
incidence of grade II–IV GVHD was 51% (95% CI: 32–
68%, Fig. 1D). Chronic GVHD was observed in 11 (40%)
of the patients, with six having a limited form and ﬁve
an extensive form.
In the univariate analysis, we could not ﬁnd any factor
associated with improved OS. Regarding the conditioning
regimen, we found a trend for better OS and PFS for those
who received TBI at 8 or 10 or 12 Gy in the conditioning
regimen (P = 0.088; P = 0.070).





































































Figure 1 (A) OS and PFS, (B) cumulative
incidence (CI) of relapse, (C) CI of non relapse
mortality, and (D) CI of acute GHVD II–IV
following allogeneic HSCT. HSCT, hematopoietic
stem cell transplantation; OS, overall survival;
PFS, progression-free survival.
Table 3 Treatment of relapse, 1 was not retreated because of infec-
tion
1 pt Alemtuzumab ? failure, lenalidomide ? failure,
bendamustine ? failure
1 pt Lenalidomide and radiotherapy ? PR
1 pt Alemtuzumab and 3 DLI ? PR and progressed
1 pt Alemtuzumab and 2 DLI ? CR complicated by
an acute grade IV GVHD (died
from pulmonary carcinoma)
1 pt Pentostatin and DLI ? CR of short duration,
retreated with bendamustine and
lenalidomide ? failure
1 pt A short course of alemtuzumab ? failure, 2 cycles
of pentostatin ? failure
1 pt Alemtuzumab and 1 DLI ? failure
1 pt 1 DLI ? failure
1 pt Pentostatin ? failure
1 pt Received a second allogeneic transplantation,
progressed, received
pentostatin ? failure
CR, complete remission; DLI, donor lymphocyte infusions; GVHD,
graft-versus-host disease; PR, partial response.
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Discussion
T-PLL is a rare disease for which treatment remains very
disappointing and outcome very dismal. HSCT has been
proposed to improve leukemic control and OS, and several
case reports suggested a possible beneﬁt from an immune
graft-versus-leukemia (GVL) effect (8–14).
Two recent registry analyses of patients treated with allo-
geneic HSCT have been reported (15, 16). The CIBMTR
registry included both B- and T-cell PLL with limited infor-
mation on the group of 21 patients with T-PLL. The median
PFS for these patients was 5.1 months with a relatively short
median follow-up. The EBMT and the Royal Marsden Con-
sortium database reported at 3 yr an OS and relapse-free sur-
vival of 21% and 19%, respectively (14). This retrospective
analysis included 41 patients transplanted at a median year
of 2004, with more than 50% receiving a standard myeloab-
lative conditioning regimen.
In the current series, OS and PFS were, respectively, 36%
and 26% at 3 yr. A number of reasons may account for the
difference between these results. The current study was per-
formed more recently (median year of transplant: 2009),
with more than half of the patients receiving a reduced-
intensity conditioning regimen (Table 4). We could not ﬁnd
a prognostic factor associated with a better outcome, and this
might be due to the small number of heterogeneous patients
analyzed. A large proportion of patients had received ale-
mtuzumab subcutaneously either prior transplantation or for
post-transplantation relapse. Dearden et al. (6) reported a
better efﬁcacy of alemtuzumab delivered intravenously. All
patients treated in this series received alemtuzumab subcuta-
neously mainly for practical reason and better tolerance.
Nevertheless, despite an encouraging response rate, the
current analysis conﬁrms that relapse after HSCT remains a
matter of concern, even late after HSCT. Hopﬁnger et al. (7)
reported seven long-term survivors (median OS
49.6 months) among the 25 patients treated with the FMC
regimen followed by alemtuzumab, ﬁve of them were
retreated for late relapse. Dearden et al. (6) reported an OS
at 48 months at 37% for those who received alemtuzumab
iv as ﬁrst-line treatment, some of them having been trans-
planted. In our series, 22% had a prolonged survival beyond
36 months.
Therefore, appropriate and close follow-up must be main-
tained to detect such relapse. Additionally, preemptive ther-
apy (early DLI) should be considered to enhance the GVL
effect.
We conclude that HSCT may lead to long-term survival
in patients with T-PLL following induction treatment. Given
the rarity of this disease, an international collaborative effort
is needed to further clarify the role of allogeneic transplanta-
tion in this devastating disease.
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